Neoadjuvant immunochemotherapy shows promising outcomes in esophageal cancer.

A multicenter retrospective study evaluated neoadjuvant immunochemotherapy involving PD-1 agents plus platinum-based chemotherapy for 213 patients with resectable esophageal cancer. The study reported a high pathological complete response (PCR) rate of 31.9%, with a complete tumor resection (R0) rate of 99.1%. Additionally, two-year disease-free survival (DFS) and overall survival (OS) rates were notable at 78.9% and 80.9%, respectively, highlighting the treatment’s efficacy and manageable toxicity.